• Je něco špatně v tomto záznamu ?

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis

M. Capra, T. Martin, P. Moreau, R. Baker, L. Pour, CK. Min, X. Leleu, M. Mohty, MR. Segura, M. Turgut, R. LeBlanc, ML. Risse, L. Malinge, S. Schwab, M. Dimopoulos

. 2022 ; 107 (6) : 1397-1409. [pub] 20220601

Jazyk angličtina Země Itálie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018173

Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The phase III IKEMA study (clinicaltrials gov. Identifier: NCT03275285) investigated isatuximab (Isa) with carfilzomib and dexamethasone (Kd) versus Kd in relapsed MM. This subgroup analysis examined results from patients with RI, defined as estimated glomerular filtration rate <60 mL/min/1.73 m2. Addition of Isa prolonged progression-free survival (PFS) in patients with RI (hazard ratio: 0.27; 95% confidence interval [CI]: 0.11-0.66; median PFS not reached for Isa-Kd versus 13.4 months for Kd [20.8-month follow-up]). Complete renal responses occurred more frequently with Isa-Kd (52.0%) versus Kd (30.8%) and were durable in 32.0% versus 7.7% of patients, respectively. Treatment exposure was longer with Isa-Kd, with median number of started cycles and median duration of exposure of 20 versus 9 cycles and 81.0 versus 35.7 weeks for Isa-Kd versus Kd, respectively. Among patients with RI, the incidence of patients with grade ≥3 treatment-emergent adverse events was similar between the two arms (79.1% in Isa-Kd vs. 77.8% in Kd). In summary, the addition of Isa to Kd improved clinical outcomes with a manageable safety profile in patients with RI, consistent with the benefit observed in the overall IKEMA study population.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018173
003      
CZ-PrNML
005      
20240528151004.0
007      
ta
008      
220720s2022 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2021.279229 $2 doi
035    __
$a (PubMed)34647444
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Capra, Marcelo $u Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre. marcelocapra@hotmail.com
245    10
$a Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis / $c M. Capra, T. Martin, P. Moreau, R. Baker, L. Pour, CK. Min, X. Leleu, M. Mohty, MR. Segura, M. Turgut, R. LeBlanc, ML. Risse, L. Malinge, S. Schwab, M. Dimopoulos
520    9_
$a Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The phase III IKEMA study (clinicaltrials gov. Identifier: NCT03275285) investigated isatuximab (Isa) with carfilzomib and dexamethasone (Kd) versus Kd in relapsed MM. This subgroup analysis examined results from patients with RI, defined as estimated glomerular filtration rate <60 mL/min/1.73 m2. Addition of Isa prolonged progression-free survival (PFS) in patients with RI (hazard ratio: 0.27; 95% confidence interval [CI]: 0.11-0.66; median PFS not reached for Isa-Kd versus 13.4 months for Kd [20.8-month follow-up]). Complete renal responses occurred more frequently with Isa-Kd (52.0%) versus Kd (30.8%) and were durable in 32.0% versus 7.7% of patients, respectively. Treatment exposure was longer with Isa-Kd, with median number of started cycles and median duration of exposure of 20 versus 9 cycles and 81.0 versus 35.7 weeks for Isa-Kd versus Kd, respectively. Among patients with RI, the incidence of patients with grade ≥3 treatment-emergent adverse events was similar between the two arms (79.1% in Isa-Kd vs. 77.8% in Kd). In summary, the addition of Isa to Kd improved clinical outcomes with a manageable safety profile in patients with RI, consistent with the benefit observed in the overall IKEMA study population.
650    _2
$a humanizované monoklonální protilátky $7 D061067
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
650    _2
$a dexamethason $x škodlivé účinky $7 D003907
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x komplikace $x farmakoterapie $7 D009101
650    _2
$a oligopeptidy $7 D009842
650    12
$a renální insuficience $x komplikace $7 D051437
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Martin, Thomas $u Department of Medicine, University of California at San Francisco, San Francisco, CA
700    1_
$a Moreau, Philippe $u Department of Hematology, University of Nantes, Nantes
700    1_
$a Baker, Ross $u Perth Blood Institute, Murdoch University, Perth
700    1_
$a Pour, Ludek $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Min, Chang-Ki $u Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul
700    1_
$a Leleu, Xavier $u Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex
700    1_
$a Mohty, Mohamad $u Department of Hematology, Hôpital Saint-Antoine, Sorbonne University, INSERM UMRs 938, Paris $7 xx0317729
700    1_
$a Segura, Marta Reinoso $u Hospital Universitario Virgen del Rocio, Sevilla
700    1_
$a Turgut, Mehmet $u Department of Hematology, Ondokuz Mayıs University Faculty of Medicine, Samsun
700    1_
$a LeBlanc, Richard $u Hôpital Maisonneuve-Rosemont, Université de Montréal
700    1_
$a Risse, Marie-Laure $u Sanofi Research and Development, Vitry/Alfortville
700    1_
$a Malinge, Laure $u Aixial, Boulogne-Billancourt
700    1_
$a Schwab, Sandrine $u Sanofi Research and Development, Vitry/Alfortville
700    1_
$a Dimopoulos, Meletios $u Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 107, č. 6 (2022), s. 1397-1409
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34647444 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20240528151001 $b ABA008
999    __
$a ok $b bmc $g 1821981 $s 1169416
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 107 $c 6 $d 1397-1409 $e 20220601 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

    Možnosti archivace